Development and assessment of human adenovirus type 11 as a gene transfer vector.
about
Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Development of adenoviral vector-based mucosal vaccine against influenza.Directed evolution generates a novel oncolytic virus for the treatment of colon cancerAdenoviral vector immunity: its implications and circumvention strategies.Transduction and oncolytic profile of a potent replication-competent adenovirus 11p vector (RCAd11pGFP) in colon carcinoma cells.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Evaluation of adenovirus vectors containing serotype 35 fibers for vaccinationCurrent strategies and future directions for eluding adenoviral vector immunityA novel and simple method for rapid generation of recombinant porcine adenoviral vectors for transgene expressionGene therapy of benign gynecological diseases.Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 HexonOncolytic adenoviruses - selective retargeting to tumor cells.Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirusGene therapy targeting to tumor endothelium.T-cell immunity generated by recombinant adenovirus vaccines.Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model.The role of liver sinusoidal cells in hepatocyte-directed gene transfer.Adenoviral producer cellsOncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Applying genomic and bioinformatic resources to human adenovirus genomes for use in vaccine development and for applications in vector development for gene delivery.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Getting genetic access to natural adenovirus genomes to explore vector diversity.Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives.A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responsesAdenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells.A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.Development of Novel Vaccines Against Infectious Diseases Based on Chimpanzee Adenoviral Vector.Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver.Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D.The Arg279Gln [corrected] substitution in the adenovirus type 11p (Ad11p) fiber knob abolishes EDTA-resistant binding to A549 and CHO-CD46 cells, converting the phenotype to that of Ad7p.Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice.Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent.Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
P2860
Q26782083-F0B940AE-6833-485C-BC91-CE3A9E658CEFQ26995655-FCDE7A14-3504-479F-A5BA-9AAFF1043157Q30226988-B7EE09BF-6B5E-46C2-8A06-ADF9CAEBD8B1Q30396642-B22AB984-178B-4245-BAE3-20A2C4895E1DQ33344440-B368E252-638E-43A5-A151-6617C65379AAQ33565630-66B6E8CA-5CF5-440B-9C2C-32618BE9AEC2Q33859402-59464AE2-A204-48DD-9653-F7C1B100CC10Q33906116-CAD1339D-D7D2-4965-AFBF-0A7A27B95677Q34507185-B682DA10-2444-46C2-9EB5-E7F2D37A1151Q34585554-68ADEE9C-9FCE-47A4-8A78-8BA7809E2901Q35641856-00F0995B-1020-43BB-9E22-AB68A4AD0A91Q35770271-07F8665B-AB72-4C93-9B23-7A397E3FCC94Q36058021-DA089F45-F025-4034-ABEB-C848F4F12E66Q36318189-F4F968CB-B571-44E7-923E-D575419E80BCQ36642630-07FE4FE4-1EC3-4F7D-A00F-869EE0EC877DQ36649681-D1F2CE83-F815-4BC7-A5DB-0F7F22EE6026Q36837129-E4E04539-E185-4D28-A934-4FE94EC06005Q37309252-16FE3E42-6340-48EF-AF1F-7F349464E85DQ37641568-318AB87B-1C96-4345-92EC-E1E5A769729EQ37945217-FB4251E1-1729-4F74-A91F-11F9CA9356C4Q38033591-CA15B98B-2DED-45FA-A6D7-7572C6584241Q38613979-F8AA2739-6239-444D-904C-D7C625256AAFQ38614156-7FCB1984-9D31-47BC-A455-4B4216284A0CQ39437315-BC03044F-14B7-4F65-B5C0-A00D5743C971Q39442539-1E9988D7-9A76-431E-92A2-25F3CBDA1EC8Q39669977-868EF6EF-E99D-459D-BF93-2571D337309FQ39906552-11378466-04A0-4061-9F81-859E58B35552Q40213253-F4FB0585-453B-4FF9-A311-5C8B1FCDEA51Q40223632-F16EB32C-7C10-4E84-89CE-1FA32471EBFDQ40250421-4C0EB86E-BD63-48EB-9980-929E75A68235Q40259665-1028B81E-C8F9-4EB0-A493-C75983FF83CFQ41786777-B3EEAA9D-81F0-4689-BEED-EFFC225DAB88Q41900379-0AD3A499-6817-422E-8D8C-69DB7860E2DAQ41928339-8905A528-842E-4494-BB46-343345705B56Q42236177-3B06FA6D-B60E-44F6-83E7-21D7476E6840Q45856784-F3904B11-C840-4C8B-9DB0-7DBA16125151Q45875332-9DBA132E-C90D-434D-8492-B07473CB0963Q45876668-1C01AF1D-B262-4485-B039-CED547FDF6B3
P2860
Development and assessment of human adenovirus type 11 as a gene transfer vector.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Development and assessment of human adenovirus type 11 as a gene transfer vector.
@en
type
label
Development and assessment of human adenovirus type 11 as a gene transfer vector.
@en
prefLabel
Development and assessment of human adenovirus type 11 as a gene transfer vector.
@en
P2093
P2860
P1433
P1476
Development and assessment of human adenovirus type 11 as a gene transfer vector.
@en
P2093
André Lieber
Anuj Gaggar
Daniel Stone
Nelson DiPaolo
Qinghua Feng
Shaoheng Ni
Volker Sandig
Zong-Yi Li
P2860
P304
P356
10.1128/JVI.79.8.5090-5104.2005
P407
P577
2005-04-01T00:00:00Z